P18-12 LB. Phase I Clinical Trial with a New Recombinant MVA-BN®-multiantigen Vaccine: High Responder Rate and Considerable Breadth of Immunological Response

T Overton, D Schmidt,J Hain, G Virgin, R Steigerwald, U Dirmeier,E Jordan,T Meyer,P Young,A Ludvigsen,R Nichols,P Chaplin

Retrovirology（2009）

Cited 1|Views18
No score
Key words
Cellular Immune Response,Vaccine Candidate,Vaccinia,Treatment Interruption,Responder Rate
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined